Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 2,451-2,475 of 3,186
CompletedNCT04673851

Horyzons: Implementation in Clinical Practice

This study exists to see whether a guided support group is workable and worth testing more broadly. Researchers are trying to understand whether a guided support group can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 16 Years to 35 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia
CompletedNCT04748679

Cognitive Behavioral Therapy (CBT) Study Evaluating the Updating of Persecutory Beliefs

This study exists to compare options and see whether cognitive behavioural therapy, a structured talking treatment, offers something meaningfully different. Researchers are trying to understand what cognitive behavioural therapy, a structured talking treatment, can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanderbilt University Medical Center
Condition
Schizophrenia
CompletedNCT01006551

Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

This study exists to see whether a medication treatment is workable and worth testing more broadly. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 6 Years to 19 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia
TerminatedNCT03669640

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

This study exists to explore whether this type of care could improve care and understanding. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Japan, Spain, Ukraine, United States
Sponsor
Hoffmann-La Roche
Condition
Schizophrenia
CompletedNCT03829280

Cognitive Adaption Training-Effectiveness in Real-world Settings and Mechanism of Action (CAT-EM)

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
The University of Texas Health Science Center at San Antonio
Condition
Schizophrenia
TerminatedNCT04210557

Models of Auditory Hallucination

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
CompletedNCT02067975

Tryptophan MRI in People With Schizophrenia and Healthy Controls

This study exists to compare options and see whether blood tests and biological markers offers something meaningfully different. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT05532683

Feasibility Trial of a Lifestyle Intervention for CHR-P

This study exists to see whether psychoeducation, a guided learning and support program, is workable and worth testing more broadly. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve sleep, daily rhythms, and longer-term stability.

SchizophreniaOtherFrom 13 Years to 17 Years
Countries
United States
Sponsor
University of California, Los Angeles
Condition
Schizophrenia
CompletedNCT02969382

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

This study exists to understand whether a medication treatment is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
Hungary, Romania, Russian Federation, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT02970929

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

This study exists to understand how the medication Safety holds up over time after the earliest research stage. Researchers are trying to understand how people respond to the medication Safety in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
Hungary, Romania, Russian Federation, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
RecruitingNCT06482554

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

This study exists to see whether this type of care can make care clearer and more responsive. Researchers are trying to understand whether this type of care can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Louisiana State University Health Sciences Center Shreveport
Condition
Schizophrenia
CompletedNCT04072354

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

This study exists to understand whether a digital app or remote support tool is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 13 Years to 65 Years
Countries
Bulgaria, Colombia, Russian Federation, Serbia, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT01940159

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT04865835

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

This study exists to see whether acceptance and commitment therapy, a talking treatment, can play a useful role in care. Researchers are trying to understand whether acceptance and commitment therapy, a talking treatment, can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT04369391

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05463770

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05402111

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05848700

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05542264

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT01994473

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

This study exists to better understand the safety of blood tests and biological markers and how manageable it feels in practice. Researchers are trying to understand how people respond to blood tests and biological markers in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT04092686

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

This study exists to understand whether a digital app or remote support tool is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Bulgaria, Croatia, Latvia, Russian Federation, Serbia, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT04524403

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Corcept Therapeutics
Condition
Schizophrenia
TerminatedNCT03077347

The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
United States
Sponsor
University of California, Davis
Condition
Schizophrenia
TerminatedNCT05643170

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

This study exists to understand how questionnaires and follow-up reports holds up over time after the earliest research stage. Researchers are trying to understand whether questionnaires and follow-up reports can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
United States | Clinical Trials | HopeStage Research